Melanoma

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
Troels Holz Borch, Rikke Andersen, Per Kongsted, Özcan Met, Mads Hald Andersen, Per thor Straten, Marco Donia, Inge Marie Svane

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P67; DOI: 10.1186/2051-1426-2-S3-P67
TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling
Ileana S Mauldin, Craig L Slingluff, Ena Wang

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P225; DOI: 10.1186/2051-1426-2-S3-P225
Use of high throughput T cell receptor (TCR) DNA sequencing to characterize T cell infusion products and track clonal expansion in vivo
Madeleine Strohl, Hallie Graor, Mei Zhang, Isabelle Rivers-McCue, John Ammori, Julian Kim

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P143; DOI: 10.1186/2051-1426-2-S3-P143
CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
Kim Margolin, Hing C Wong, Chihiro Morishima, Liza Hernandez, Marc Ernstoff, Peter R Rhode, Thomas A Waldmann

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P79; DOI: 10.1186/2051-1426-2-S3-P79
Turning tumor inhibition into activation: engineering T cells with chimeric signaling receptors
Ramona Schlenker, Matthias Leisegang, Wolfgang Uckert, Elfriede Noessner

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P248; DOI: 10.1186/2051-1426-2-S3-P248
Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
Yago Pico de Coaña, Isabel Poschke, Yuya Yoshimoto, Sara Karlberg, Maria Nyström, Maria Wolodarski, Johan Hansson, Giuseppe Masucci, Rolf Kiessling

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P231; DOI: 10.1186/2051-1426-2-S3-P231
The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
Sara M Mangsbo, Niina Veitonmäki, Erika Gustfson, Karin Enell Smith, Christina Furebring, Per Norlén, Malin Lindstedt, Thomas H Tötterman, Peter Ellmark

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P251; DOI: 10.1186/2051-1426-2-S3-P251
Specific increase in T cell potency via structure-based design of a T cell receptor for adoptive immunotherapy
Karolina Malecek, Arsen Grigoryan, Shi Zhong, Wei Jun Gu, Laura A Johnson, Steven A Rosenberg, Timothy Cardozo, Michelle Krogsgaard

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P28; DOI: 10.1186/2051-1426-2-S3-P28
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
Chihiro Morishima, Douglas G McNeel, Manish R Patel, Holbrook Kohrt, Thomas A Waldmann, John A Thompson, Kevin Conlon, Paul M Sondel, Heather Wakelee, Mary L Disis, Stephen P Creekmore, Jeffrey S Miller

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P80; DOI: 10.1186/2051-1426-2-S3-P80
Mechanisms of TIGIT-driven immune suppression in cancer
Sema Kurtulus, Kaori Sakuishi, Huiyuan Zhang, Nicole Joller, Dewar Tan, Mark Smyth, Vijay Kuchroo, Ana Anderson

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) O13; DOI: 10.1186/2051-1426-2-S3-O13

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages